These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Flecainide acetate in dogs with ischemic tachyarrhythmia. An electrophysiologic study. Cha YM; Zhang AP; Liu L; Sun JP; Huang W Chin Med J (Engl); 1988 Oct; 101(10):710-4. PubMed ID: 3150701 [No Abstract] [Full Text] [Related]
4. [Effects of flecainide in patients with non-sustained ventricular tachycardia and impaired left ventricular function]. De Marzio P; Morelli S; Suppa M; Caputo V; Mango L; Guido V; Cardoni F; Gnecchi M; Aguglia F Minerva Cardioangiol; 1991; 39(1-2):35-9. PubMed ID: 1906997 [TBL] [Abstract][Full Text] [Related]
5. Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. Lynch JJ; DiCarlo LA; Montgomery DG; Lucchesi BR Pharmacology; 1987; 35(4):181-93. PubMed ID: 3118399 [TBL] [Abstract][Full Text] [Related]
6. Unusual electrocardiogram findings in a preterm infant after fetal tachycardia with hydrops fetalis treated with flecainide. Trotter A; Kaestner M; Pohlandt F; Lang D Pediatr Cardiol; 2000; 21(3):259-62. PubMed ID: 10818187 [TBL] [Abstract][Full Text] [Related]
7. [Drug-induced intrahepatic cholestasis caused by flecainide acetate and enalapril]. Mikloweit P; Bienmüller H Internist (Berl); 1987 Mar; 28(3):193-5. PubMed ID: 3034817 [No Abstract] [Full Text] [Related]
8. Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations. Miyamoto K; Aiba T; Kimura H; Hayashi H; Ohno S; Yasuoka C; Tanioka Y; Tsuchiya T; Yoshida Y; Hayashi H; Tsuboi I; Nakajima I; Ishibashi K; Okamura H; Noda T; Ishihara M; Anzai T; Yasuda S; Miyamoto Y; Kamakura S; Kusano K; Ogawa H; Horie M; Shimizu W Heart Rhythm; 2015 Mar; 12(3):596-603. PubMed ID: 25496985 [TBL] [Abstract][Full Text] [Related]
9. [An electrophysiologic study on the anti-ischemic arrhythmia effect of flecainide]. Zha YM Zhonghua Xin Xue Guan Bing Za Zhi; 1988 Oct; 16(5):294-7. PubMed ID: 3148452 [No Abstract] [Full Text] [Related]
10. Flecainide monotherapy for catecholaminergic polymorphic ventricular tachycardia: Perspectives and limitations. Napolitano C Heart Rhythm; 2016 Feb; 13(2):614-5. PubMed ID: 26498259 [No Abstract] [Full Text] [Related]
11. Lessons from the cardiac arrhythmia suppression trial. Garratt C; Ward DE; Camm AJ BMJ; 1989 Sep; 299(6703):805-6. PubMed ID: 2510839 [No Abstract] [Full Text] [Related]
12. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). Epstein AE; Hallstrom AP; Rogers WJ; Liebson PR; Seals AA; Anderson JL; Cohen JD; Capone RJ; Wyse DG JAMA; 1993 Nov; 270(20):2451-5. PubMed ID: 8230622 [TBL] [Abstract][Full Text] [Related]
14. [Effect of class I anti-arrhythmia agents on the signal-averaged ECG]. Goedel-Meinen L; Hofmann M; Schmidt G; Barthel P; Baedeker W; Blömer H Herz; 1988 Jun; 13(3):188-96. PubMed ID: 3136064 [TBL] [Abstract][Full Text] [Related]
15. Flecainide treatment of fetal tachycardia and hydrops fetalis in a twin pregnancy. Gerli S; Clerici G; Mattei A; Di Renzo GC Ultrasound Obstet Gynecol; 2006 Jul; 28(1):117. PubMed ID: 16736448 [No Abstract] [Full Text] [Related]
16. [Estimation of the long-term efficacy of anti-arrhythmia treatment with flecainide in ventricular tachycardia]. Fauchier JP; Cosnay P; Babuty B; Moquet B; Rouesnel P; Estepo J Arch Mal Coeur Vaiss; 1990 Jan; 83(1):77-83. PubMed ID: 2106308 [TBL] [Abstract][Full Text] [Related]